Bone Biologics (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, recently announced the pricing of an underwritten public offering of common stock. The company is selling 2,538,071 shares of its common stock in the offering, each at a price to the public of $1.97, for aggregate gross proceeds of approximately $5.0 million. In addition, Bone Biologics has granted the underwriters an over-allotment option, exercisable for a period of 45 days from the date of the underwriting agreement for the offering, to purchase up to an additional 253,807 common shares. Subject to customary conditions, the offering was expected to close on or about June 16, 2023. EF Hutton, division of Benchmark Investments LLC, acted as the sole book-running manager for the offering.
To view the full press release, visit https://ibn.fm/oEqwM
About Bone Biologics Corporation
Bone Biologics was founded to pursue regenerative medicine for bone. The company is undertaking work with select strategic partners that builds on the preclinical research of the Nell-1 protein. Bone Biologics is currently focusing its development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork